Advertisement

Journal of Neurology

, 254:581 | Cite as

Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia

  • I. A. F. van der MeiEmail author
  • A.-L. Ponsonby
  • T. Dwyer
  • L. Blizzard
  • B. V. Taylor
  • T. Kilpatrick
  • H. Butzkueven
  • A. J. McMichael
ORIGINAL COMMUNICATION

Abstract

Background

Adequate 25(OH)D levels are required to prevent adverse effects on bone health. Population-based data on factors associated with 25(OH)D levels of people with MS have been lacking. Objectives To examine the prevalence and determinants of vitamin D insufficiency in a population-based sample of MS cases and controls, and to compare 25(OH)D status between MS cases and controls, taking into account case disability.

Methods

We conducted a population based case-control study in Tasmania, Australia (latitude 41-3°S) on 136 prevalent cases with MS confirmed by magnetic resonance imaging and 272 community controls, matched on sex and year of birth. Measurements included serum 25(OH)D, sun exposure, skin type, dietary vitamin D intake and disability including EDSS.

Results

A high prevalence of vitamin D insufficiency was found in MS cases and controls. Among MS cases, increasing disability was strongly associated with lower levels of 25(OH)D and with reduced sun exposure. Cases with higher disability (EDSS > 3) were more likely to have vitamin D insufficiency than controls (OR = 3.07 (1.37, 6.90) for 25(OH)D >40 nmol/l), but cases with low disability were not (OR = 0.87 (0.41, 1.86)).

Conclusion

The strong associations between disability, sun exposure and vitamin D status indicate that reduced exposure to the sun, related to higher disability, may contribute to the high prevalence of vitamin D insufficiency found in this population-based MS case sample. Active detection of vitamin D insufficiency among people with MS and intervention to restore vitamin D status to adequate levels should be considered as part of the clinical management of MS.

Key words

vitamin D multiple sclerosis deficiency insufficiency sun exposure disability healthy 

References

  1. 1.
    Bergamaschi R, Romani A, Versino M, Poli R, Cosi V (1997) Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 12:247-51PubMedGoogle Scholar
  2. 2.
    Bischoff HA, Stahelin HB, Dick W, Akos R, Knecht M, Salis C, Nebiker M, Theiler R, Pfeifer M, Begerow B, Lew RA, Conzelmann M (2003) Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 18:343-51CrossRefPubMedGoogle Scholar
  3. 3.
    Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB (2004) Effect of Vitamin D on falls: a meta-analysis. JAMA 291:1999-006CrossRefPubMedGoogle Scholar
  4. 4.
    Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257-264CrossRefPubMedGoogle Scholar
  5. 5.
    Boiko A (1997) Data collection guidelines for questionnaires to be used in case-control studies of multiple sclerosis. Neurology 49:S75-0PubMedGoogle Scholar
  6. 6.
    Bouillon R, Okamura WH, Norman AW (1995) Structure-Function Relationships in the Vitamin D Endocrine System. Endocrine Rev 16:200-57Google Scholar
  7. 7.
    Cantorna MT, Hayes CE, DeLuca HF (1996) 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 93:7861-864CrossRefPubMedGoogle Scholar
  8. 8.
    Cohen JA (1968) nominal scale agreement with provision for scaled disagreement or partial credit. Am Psychol Assoc 70:213-19Google Scholar
  9. 9.
    Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C, Shen V, Lindsay R (1998) Fracture history and bone loss in patients with MS. Neurology 51:1161-165PubMedGoogle Scholar
  10. 10.
    Dwyer T, Blizzard L, Gies PH, Ashbolt R, Roy C (1996) Assessment of habitual sun exposure in adolescents via questionnaire-a comparison with objective measurement using polysulphone badges. Melanoma Res 6:231-39CrossRefPubMedGoogle Scholar
  11. 11.
    Dwyer T, Muller HK, Blizzard L, Ashbolt R, Phillips G (1998) The use of spectrophotometry to estimate melanin density in Caucasians. Cancer Epidemiol Biomarkers Prev 7:203-06PubMedGoogle Scholar
  12. 12.
    Dwyer T, Prota G, Blizzard L, Ashbolt R, Vincensi MR (2000) Melanin density and melanin type predict melanocytic naevi in 19-0 year olds of northern European ancestry. Melanoma Res 10:387-94CrossRefPubMedGoogle Scholar
  13. 13.
    Embry AF, Snowdon LR, Vieth R (2000) Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 48:271-72CrossRefPubMedGoogle Scholar
  14. 14.
    Eyles DW, Brown J, Mackay-Sim A, McGrath J, Feron F (2002) Vitamin D3 and brain development. Neuroscience. 1-4Google Scholar
  15. 15.
    Feskanich D, Willett WC, Colditz GA (2003) Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am J Clin Nutr 77:504-11PubMedGoogle Scholar
  16. 16.
    Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Hamada T, Miyasaka K, et al. (1999) Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 166:47-2CrossRefPubMedGoogle Scholar
  17. 17.
    Goldberg P, Fleming MC, Picard EH (1986) Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 21:193-00CrossRefPubMedGoogle Scholar
  18. 18.
    Holick MF (1994) McCollum Award Lecture, 1994: vitamin D–new horizons for the 21st century. Am J Clin Nutr 60:619-30PubMedGoogle Scholar
  19. 19.
    Holick MF (2004) Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362-71PubMedGoogle Scholar
  20. 20.
    Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135:317-22PubMedGoogle Scholar
  21. 21.
    Jablonski NG, Chaplin G (2000) The evolution of human skin coloration. J Hum Evol 39:57-06CrossRefPubMedGoogle Scholar
  22. 22.
    Jorde R, Waterloo K, Saleh F, Haug E, Svartberg J (2005) Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels The Tromso study. J NeurolGoogle Scholar
  23. 23.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-452PubMedGoogle Scholar
  24. 24.
    Lemire JM (1992) Immunomodulatory Role of 1,25-Dihydroxyvitamin D3. Journal of Cellular Biochemistry 49:26-1CrossRefPubMedGoogle Scholar
  25. 25.
    Lemire JM, Archer DC (1991) 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 87:1103-107CrossRefPubMedGoogle Scholar
  26. 26.
    Magaziner J, Hawkes W, Hebel JR, Zimmerman SI, Fox KM, Dolan M, Felsenthal G, Kenzora J (2000) Recovery from hip fracture in eight areas of function. J Gerontol A Biol Sci Med Sci 55:M498-07PubMedGoogle Scholar
  27. 27.
    Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT (2003) Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 134:128-32CrossRefPubMedGoogle Scholar
  28. 28.
    Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, Ascherio A (2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62:60-5PubMedGoogle Scholar
  29. 29.
    Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994) High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687-692PubMedGoogle Scholar
  30. 30.
    Niino M, Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Tashiro K (2000) Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci 177:65-1CrossRefPubMedGoogle Scholar
  31. 31.
    Nowson CA, Margerison C (2002) Vitamin D intake and vitamin D status of Australians. Med J Aust 177:149-52PubMedGoogle Scholar
  32. 32.
    Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, Eisen KA, Purves SJ, Low MD, Brandejs V et al. (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180-85PubMedGoogle Scholar
  33. 33.
    Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-31CrossRefPubMedGoogle Scholar
  34. 34.
    Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sorensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sa M, Salemi G, Savettieri G, Hillert J, Compston DA (2005) Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64:1144-151PubMedGoogle Scholar
  35. 35.
    Salonen JT, Tuomilehto J, Nissinen A, Kaplan GA, Puska P (1989) Contribution of risk factor changes to the decline in coronary incidence during the North Karelia project: a within-community analysis. Int J Epidemiol 18:595-01CrossRefPubMedGoogle Scholar
  36. 36.
    Simmons RD, Ponsonby AL, van der Mei IA, Sheridan P (2004) What affects your MS? Responses to an anonymous, Internet-based epidemiological survey. Mult Scler 10:202-11CrossRefPubMedGoogle Scholar
  37. 37.
    Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB (1984) A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 34:1368-372PubMedGoogle Scholar
  38. 38.
    Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A (2005) 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 11:266-71CrossRefPubMedGoogle Scholar
  39. 39.
    Steckley JL, Dyment DA, Sadovnick AD, Risch N, Hayes C, Ebers GC (2000) Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Canadian Collaborative Study Group. Neurology 54:729-32PubMedGoogle Scholar
  40. 40.
    Studzinski GP, Moore DC (1995) Sunlight-can it prevent as well as cause cancer? Cancer Res 55:4014-022PubMedGoogle Scholar
  41. 41.
    Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R (1998) Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 68:854-58PubMedGoogle Scholar
  42. 42.
    van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, Butzkueven H, Kilpatrick T (2003) Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 327:316CrossRefPubMedGoogle Scholar
  43. 43.
    Vieth R (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69:842-56PubMedGoogle Scholar
  44. 44.
    Vieth R, Chan PC, MacFarlane GD (2001) Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 73:288-94PubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  • I. A. F. van der Mei
    • 1
    Email author
  • A.-L. Ponsonby
    • 2
    • 3
  • T. Dwyer
    • 2
    • 3
  • L. Blizzard
    • 3
  • B. V. Taylor
    • 4
  • T. Kilpatrick
    • 5
  • H. Butzkueven
    • 5
  • A. J. McMichael
    • 6
  1. 1.Menzies Research InstituteHobart, TasmaniaAustralia
  2. 2.Murdoch Childrens Research InstituteMelbourneAustralia
  3. 3.Menzies Research InstituteHobartAustralia
  4. 4.Christchurch School of Medicine & Health SciencesUniversity of OtagoChristchurchNew Zealand
  5. 5.Howard Florey InstituteThe University of MelbourneMelbourneAustralia
  6. 6.National Centre for Epidemiology and Population HealthThe Australian National UniversityCanberraAustralia

Personalised recommendations